Compliance-Driven Growth: HRSA Audit Readiness as a BD Lever

Not legal or compliance advice: Consult your organization's legal counsel, 340B compliance officer, external auditor, HRSA Office of Pharmacy Affairs (OPA), and Apexus before acting on anything below. Verify all procedures and expectations against the most current HRSA guidance and Apexus Answers.

Premise of this article: In 340B business development, compliance is often framed as a brake on growth. The opposite is closer to the truth. Programs that invest in continuous audit readiness tend to grow more confidently, sustainably, and defensibly than programs that treat audits as episodic events.

Why audit readiness is a growth enabler

A covered entity that cannot demonstrate clean eligibility determinations, well-documented contract pharmacy oversight, reliable child site records, and disciplined duplicate discount prevention is a fragile program — regardless of how much patient benefit it generates. Growth built on a fragile compliance foundation creates three problems:

1. Expansion amplifies unresolved weaknesses. New sites, new contract pharmacies, or new service lines inherit whatever controls already exist.
2. Findings narrow options. A material audit finding can trigger corrective action plans, repayments, and in some circumstances removal from the program.
3. Leadership loses appetite for expansion. Boards and executive teams that experience a difficult audit often pause new initiatives.

A program that is continuously audit-ready produces clean data, disciplined documentation, and trustworthy reporting. Those same artifacts make planning new child sites, evaluating contract pharmacy additions, and modeling service expansions far easier.

Reframe the conversation: "Are we audit-ready?" is the same question as "Do we understand our program well enough to grow it responsibly?"

Overview of the HRSA audit framework (conceptual)

HRSA conducts audits of covered entities to verify compliance with Section 340B and related guidance. Manufacturer-initiated audits also occur. Areas commonly examined — at a conceptual level — include:

• Patient eligibility. Whether individuals met the HRSA patient definition in effect at the time.
• Duplicate discount prevention. Whether Medicaid duplicate discounts were avoided.
• Diversion prevention. Whether 340B drugs were provided only to eligible patients.
• Contract pharmacy oversight. Whether the entity maintained written contracts and performed oversight.
• Child site eligibility. Whether offsite outpatient facilities were appropriately registered.
• Policies and procedures. Whether the entity maintained and followed written P&Ps.
• Self-audits and independent audits. Whether the entity conducted appropriate reviews.

Do not treat the above as a definitive scope: The conceptual categories are durable; specific expectations evolve. Confirm current HRSA audit protocol with counsel and HRSA OPA.

The self-audit program and independent audit expectations

A self-audit program is a structured, repeatable internal review. A mature self-audit program typically includes written scope and methodology; defined cadence; qualified reviewers; a findings log; follow-through evidence; and management reporting.

Independent audits — sometimes conducted by external accounting or consulting firms with 340B competency — complement self-audits. For certain entity types, independent audits are required; for others, they are strongly recommended.

Corrective action plans (CAPs)

A workable CAP generally includes a clear finding statement; root cause analysis; remediation steps; ownership; evidence of completion; a re-testing plan; and repayment or remediation of affected transactions where required.

CAP mindset: A finding around child site eligibility at a newly acquired clinic might drive: updated OPAIS registration confirmation procedures, a pre-go-live eligibility checklist, training for the clinic operations team, and an annual audit of site registration accuracy. The goal is not just fixing one site — it is preventing the category of error.

Mock audits

Mock audits simulate an HRSA audit before one occurs. Benefits frequently observed include surfacing gaps while they can still be fixed, building team familiarity with evidence requests, testing document retrieval speed, validating that written policies match practice, and exercising the oversight committee on real issues.

A mock audit is most useful when conducted by a qualified external reviewer with 340B audit experience, scoped to mirror HRSA's conceptual areas, treated seriously, and followed by a CAP for every issue identified.

Mock audits and BD planning: Scheduling a mock audit before a major expansion lets you enter the expansion from a verified baseline.

Documentation habits that also enable BD

The documentation that keeps a program audit-ready supports good business development:

• A living policies-and-procedures set.
• Eligibility logic documented in plain language and mapped to system configurations.
• Child site inventory with OPAIS registration, effective dates, and cost center/scope documentation.
• Contract pharmacy registry with each location's contract, scope, go-live date, most recent self-audit, and open findings.
• Training records.
• Oversight committee minutes.
• Data lineage notes.

Clean documentation means that when the BD team asks, "Where would we add a new child site?", the answers are a query away.

Building a culture of continuous readiness

• Ownership is named, not implied.
• Findings are welcomed, not hidden.
• Documentation is maintained in real time.
• Training is ongoing.
• Leadership asks about compliance routinely.
• Vendors are treated as extensions, not replacements.

Sample readiness cadence

Monthly

• Review Medicaid Exclusion File status and any planned changes.
• Spot-check eligibility determinations at each registered site.
• Reconcile contract pharmacy dispensing data against eligibility expectations.
• Review new-hire training completion.
• Log, triage, and assign emerging issues.

Quarterly

• Formal self-audit sample across eligibility, diversion, and duplicate discount prevention.
• Contract pharmacy oversight review at each location.
• Child site review: OPAIS status, registration effective dates, changes.
• Policies and procedures change log review.
• Oversight committee meeting with minutes.
• CAP status review and closure evidence.

Annually

• Comprehensive self-audit across all conceptual areas.
• Independent audit where required or scheduled.
• Full policy review and re-adoption.
• Training program refresh.
• Mock audit on a rotating basis.
• Board-level compliance report.
• Vendor contract and performance review.
• Revisit the BD roadmap in light of compliance posture.

Right-size the cadence: A small FQHC will operate at a different cadence than a multi-state hospital system. The point is not volume of activity — it is demonstrable, documented, and followed-through rhythm.

Common findings and how they block growth

• Policies and procedures do not match actual practice. Expansion plans rest on a written baseline that does not describe reality.
• Eligibility determinations not consistently documented. Every new service line multiplies exposure.
• Contract pharmacy oversight is paper-only. Adding locations is reckless until oversight is real.
• Child site registration errors. Acquisition- or clinic-launch-driven growth becomes dangerous.
• Medicaid duplicate discount issues. Medicaid-heavy expansions carry outsized risk.
• Thin or inconsistent self-audit program. The organization cannot reliably demonstrate its own controls.
• Inadequate training records. Growth stretches a workforce whose competencies are not documented.

Fix the category, not just the case: Treating each finding as a one-off misses the root.

When to involve external counsel

External counsel — ideally with 340B experience — should be involved in, at minimum, significant self-audit or independent audit findings; any HRSA audit engagement; any finding with a potential repayment element; interpretation of current guidance; contracts with contract pharmacies and TPAs; structural changes; state pharmacy board inquiries; and manufacturer disputes or audit demands.

Pitfalls in compliance-driven growth

• Treating audit readiness as a binary.
• Letting compliance be a silo.
• Delegating accountability to vendors.
• Skipping root-cause analysis.
• Celebrating the absence of findings rather than the presence of controls.
• Deferring documentation "until there's time."

Bringing compliance into the BD conversation

• Invite the compliance officer to BD planning meetings by default.
• Require a pre-launch compliance review for new sites, contract pharmacies, and service lines.
• Include a compliance section in every BD business case template.
• Build a "compliance health" dashboard reviewed alongside operational metrics.
• Align annual BD planning with the annual compliance calendar.

A well-run program produces growth that compounds rather than growth that has to be unwound.

References

• Section 340B of the Public Health Service Act, 42 U.S.C. § 256b.
• HRSA Office of Pharmacy Affairs (OPA), 340B Drug Pricing Program — covered entity audit protocols and program guidance.
• Apexus Answers, including operational and compliance guidance endorsed by HRSA through the Prime Vendor Program.
• HHS Office of Inspector General (OIG), reports on the 340B program.
• HRSA 340B Program Notices and Federal Register notices relevant to audit scope.

This article is educational and does not constitute legal, tax, regulatory, compliance, or financial advice. Program rules change; verify current guidance with HRSA's Office of Pharmacy Affairs, Apexus, and qualified counsel before acting.